Mandate

Vinge advises Haypp Group in connection with the listing on Nasdaq First North Growth Market

Vinge advises Haypp Group AB (publ) (“Haypp Group”) in connection with the listing on Nasdaq First North Growth Market. The prospectus was published on 4 October 2021 and the first day of trading on Nasdaq First North Growth Market was 13 October 2021. The offering price was SEK 66 per share, corresponding to a market value of Haypp Group of approximately SEK 1,9 billion.

Haypp Group is an e-commerce business selling nicotine pouches and snus online in nine countries across Europe and in the US. The Company sells a broad selection of brands of any supplier in the category through a range of ten e-commerce platforms and brands, the largest of which is the Swedish snusbolaget.se. Haypp Group was founded in 2009 and is headquartered in Stockholm, Sweden.

The Vinge team mainly includes Christian Lindhé, Erik Sjöman, Kristian Ford (client responsible partner), Martin Svanberg and Johanne Örnfeldt Svensson (Capital Markets and Public M&A) as well as Niklas Törnell and Carl Trolle Olson (M&A).

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026